Super-API Pipeline

DRGT is dedicated to develop a proprietary pipeline that consists of Super-API compositions of several blockbusters for oncology, pain, erectile dysfunction and other unmet medical needs.

Super-API drugs are being developed using DRGT’s Super-API technology platform. The developed Super-API compositions have unique structures with improved clinical utility. These compositions are protected by global composition of matter IPs.  

Proven benefits of the Super-APIs:

Regulatory
path
Super-API Indication Development Phase
Discovery
Preclinical
Phase I
BE Pivotal / Phase II
505(b)(2)
Bioequivalence
DRGT-45Abiraterone Prostate cancer
DRGT-46Celecoxib NSAID
DRGT-99Tadalafil Erectile dysfunction
DRGT-31 Thrombin inhibitor
DRGT-19 Pneumocystis pneumonia
505(b)(1)
DRGT-18-2 Prophylaxis of organ rejection
DRGT-119 Proctology
DRGT-45-2 Prostate cancer
DRGT-96NCE Prostate cancer
DRGT-97NCE Prostate cancer
DRGT-29-2NCE Breast cancer
DRGT-109 Diabetic retinopathy
DRGT-110NCE Analgesic
DRGT-111NCE Analgesic
Long life NCE
for partnership
505(b)(2)
DRGT-56 Cystic Fibroses
DRGT-76 Cystic Fibroses
DRGT-102 Cystic Fibroses
DRGT-65 Schizophrenia
DRGT-73 Insomnia
DRGT-100 Chronic lymphocytic leukemia

Additional Super-API compounds are in discovery phase.